NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $0.33 -0.02 (-6.00%) Closing price 04:00 PM EasternExtended Trading$0.35 +0.02 (+5.78%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About BioAtla Stock (NASDAQ:BCAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioAtla alerts:Sign Up Key Stats Today's Range$0.33▼$0.3550-Day Range$0.30▼$0.6852-Week Range$0.24▼$4.02Volume565,211 shsAverage Volume987,224 shsMarket Capitalization$15.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company OverviewBioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Read More… BioAtla Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreBCAB MarketRank™: BioAtla scored higher than 62% of companies evaluated by MarketBeat, and ranked 361st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingBioAtla has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioAtla has received no research coverage in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($1.46) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioAtla's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.95% of the float of BioAtla has been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.95% of the float of BioAtla has been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News SentimentN/A News SentimentBioAtla has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Stock News HeadlinesAXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)March 4 at 7:34 AM | globenewswire.comBioAtla faces Nasdaq delisting over share price ruleFebruary 8, 2025 | msn.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.March 6, 2025 | Crypto Swap Profits (Ad)BioAtla Secures $9.2M for Clinical Program AdvancementsDecember 21, 2024 | markets.businessinsider.comBioAtla Highlights Advancements in CAB Cancer TherapyDecember 20, 2024 | markets.businessinsider.comBioAtla to sell 9.68M shares at 95.2c in registered direct offeringDecember 20, 2024 | markets.businessinsider.comBioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection PointsDecember 20, 2024 | globenewswire.comBioAtla presents data on mecbotamab vedotin in advanced NSCLCDecember 17, 2024 | markets.businessinsider.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $0.5912 on January 1st, 2025. Since then, BCAB shares have decreased by 44.4% and is now trading at $0.3290. View the best growth stocks for 2025 here. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.12. The business earned $11 million during the quarter. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an initial public offering on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. Who are BioAtla's major shareholders? BioAtla's top institutional shareholders include Anson Funds Management LP (9.52%), Acorn Capital Advisors LLC (8.34%), Highbridge Capital Management LLC (5.19%) and Tang Capital Management LLC (2.84%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman and Sylvia Mcbrinn. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings11/07/2024Today3/06/2025Next Earnings (Estimated)3/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,723.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,460,000.00 Net MarginsN/A Pretax Margin-743.79% Return on Equity-187.30% Return on Assets-96.33% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio3.11 Sales & Book Value Annual Sales$11 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.22Miscellaneous Outstanding Shares48,346,000Free Float42,786,000Market Cap$15.91 million OptionableOptionable Beta1.19 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BCAB) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNew Way To Target 2x Trades Every Monday MorningNo. 1 Stock to Buy for THIS MONDAY Heads up: Tim Bohen’s new algorithm just uncovered a dirt-cheap stock th...StocksToTrade | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | Sponsored2025 AI Blueprint: Nvidia’s more important than everAI is Big Tech’s #1 priority in 2025—Amazon, Microsoft, Google, and Meta are pouring a record $320 billion int...Weiss Ratings | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.